The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc

Molecular and Cellular Biochemistry

Volumn 250, Issue 1-2, 2003, Pages 91-105

  Li, Jun ^a,b   Kretzner, Leo ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Experimental Station   (United States)

Author keywords

Differential display; Myc; Ndrg1; Neuroblastoma; Oncogene targets

Indexed keywords

GENE PRODUCT;

ANIMAL CELL; CELL LINE; CELL TYPE; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DOWN REGULATION; FIBROBLAST; GENE ACTIVATION; GENE AMPLIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; NEUROEPITHELIOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYB; ONCOGENE MYC; PROGNOSIS; PROMOTER REGION; RAT; REVIEW; TRANSGENE;

AGAR; BLOTTING, NORTHERN; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CLONING, MOLECULAR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASES; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 0041884865     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024918328162     Document Type: Review

References (55)

1. Berthold F: Overview: Biology of neuroblastoma. In: C. Pochedly (ed). Neuroblastoma: Tumor Biology and Therapy. CRC Press, 1990, pp 1-27
2. Brodeur GM, Castleberry RP: Neuroblastoma. In: PA Pizzo, DG Poplack (eds). Principles and Practice of Pediatric Oncology. Lippincott, PA, 1993, pp 739-767
3. Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ, Brodeur GM: Biological classification of cell lines derived from human extra-cranial neural tumors. Adv Neuroblastoma Res 2: 291-306, 1988
4. DePinho RA, Schreiber-Agus N, Alt, FW: myc Family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 57: 1-46, 1991
5. Henriksson M, Lüscher B: Proteins of the Myc network: Essential regulators of cell growth and differentiation. Adv Cancer Res 68: 109-182, 1996
6. Seeger RC, Brodeur GM, Sather H et al.: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116, 1985
7. Peters MA, Taparowsky EJ: Target genes and cellular regulators of the Myc transcription complex. Crit Revs Euk Gene Expr 8: 277-296, 1998
8. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97: 3260-3265, 2000
9. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM: Targeted expression of MYCN causes neuroblastoma in transgenic mice. Embo J 16: 2985-2995, 1997
10. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB: c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. Embo J 13: 4070-4079, 1994
11. Judware R, Culp LA: Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: Differential regulation of α2, β3 and α1. Oncogene 14: 1341-1350, 1997
12. Breit S, Ashman K, Wilting J, Rossler J, Hatzi E, Fotsis T, Schweigerer L: The N-myc oncogene in human neuroblastoma cells: Down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 60: 4596-4601, 2000
13. Claassen GF, Hann SR: Myc-mediated transformation: The repression connection. Oncogene 18: 2925-2933, 1999
14. Chambery D, Mohseni-Zadeh S, de Galle B, Babajko S: N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res 59: 2898-2902, 1999
15. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus M-C, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R: N-myc enhances the expression of a a large set of genes functioning in ribosome biogenesis and protein synthesis. Embo J 20, 1383-1393, 2001
16. Liang P, Averboukh L, Pardee AB: Distribution and cloning of eukaryotic mRNAs by means of differential display: Refinements and optimization. Nucleic Acids Res 21: 3269-3275, 1993
17. Kokame K, Kato H, Miyata T: Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. J Biol Chem 271: 29659-29665, 1996
18. van Belzen N, Dinjens WNM, Diesveld MPG et al.: A novel gene upregulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasm. Lab Invest 77: 85-92, 1997
19. Lin T-M, Chang C: Cloning and characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone. Proc Natl Acad Sci USA 94: 4988-4993, 1997
20. 2+ compound. Cancer Res 58: 2182-2189, 1998
21. Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW: Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58: 4439-4444, 1998
22. Shimono A, Okuda T, Kondoh H: N-myc-dependent repression of Ndr1, a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant. Mech Devel 83: 39-52, 1999
23. Schwab M, Alitoal K, Klempnauer K-H, Varmus, HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 305: 245-248, 1983
24. Eggert A, Ho R, Ikegaki N, Liu X, Brodeur GM: Different effects of TrkA expression in neuroblastoma cell lines with and without MYCN amplification. Med Ped Oncol 35: 623-627, 2000
25. Cohn SL, Salwen H, Quasney MW, Ikegaki N, Cowan JM, Herst CV, Kennett RH, Rosen ST, DiGiuseppe JA, Brodeur GM: Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene 5: 1821-1827, 1990
26. Thiele CJ, McKeon C, Triche TJ, Ross RA, Reynolds P, Israel MA: Differential proto-oncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J Clin Inv 80: 804-811, 1987
27. Bansal R, Pfeiffer SE: Regulated galactolipid synthesis and cell surface expression in Schwann cell line D6P2T. J Neurochem 49:1902-1911, 1987
28. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690, 1995
29. Greenberg ME, Bender TP: Analysis of RNA structure and synthesis. In: Ausubel et al. (eds). Current Protocols in Molecular Biology. Wiley & Sons, 1992
30. Galderisi U, DiBernardo G, Cipollaro M et al.: Differentiation and apoptosis of neuroblastoma cells: Role of N-myc gene product. J Cell Biochem 73: 97-105, 1999
31. Ikegaki N, Bukovsky J, Kennett RH: Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. Proc Natl Acad Sci USA 83: 5929-5933, 1986
32. Foley KP, Eisenman RN: Two MAD tails: What the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim Biophys Acta 1423: M37-M47, 1999
33. Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, Grundy PE, Perlman EJ, Breslow NE, Sukumar S: High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' Tumor. Cancer Res 59: 4301-4307, 1999
34. Panero NJ, Yuen PK, Sakazume T, Fortina P, Kricka LJ, Wilding P: Evaluation of DNA fragment sizing and quantification by the Agilent 2100 Bioanalyzer. Clin Chem 46: 1851-1853, 2000
35. Nachamkin I, Panaro NJ, Li M, Ung H, Yuen PK, Kricka LJ, Wilding P: Agilent 2100 Bioanalyzer for restriction fragment length polymorphism analysis of the Campylobacter jejuni flagellin gene. J Clin Microbiol 39: 754-757
36. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H: Sequence specific DNA binding by the c-Myc protein. Science 250: 1149-1151, 1990
37. Ciccarona V, Spengler BA, Meyers MB, Biedler JL, Ross RA: Phenotypic diversification in human neuroblastoma cells: Expression of distinct neural crest lineages. Cancer Res 49: 219-225, 1989
38. Rabbitts PH, Watson JV, Lamond A et al.: Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. Embo J 4: 2009-2015, 1985
39. Thiele CJ, Reynolds P Israel MA: Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313: 404-406, 1985
40. Peverali FA, Orioli D, Tonon L et al.: Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpression. Oncogene 12: 457-462, 1996
41. Agrawal S, Jiang ZW, Zhao QY et al.: Mixed-backbone oligonucleotides as second-generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 94: 2620-2625, 1997
42. Schmajuk G, Sierakowska H, Kole R: Antisense oligonucleotides with different backbones. J Biol Chem 274: 21713-21789, 1999
43. Gandelman KY, Pfeiffer SE, Carson JH: Cyclic AMP regulation of P0 glycoprotein and myelin basic protein gene expression in semi-differentiated peripheral neurinoma cell line D6P2T. Development 106: 389-398, 1989
44. Lemaitre JM, Buckle RS, Mechali M: c-Myc in the control of cell proliferation and embryonic development. Adv Cancer Res 70: 95-144, 1996
45. Marcu KB, Bossone SA, Patel AJ: Myc function and regulation. Ann Rev Biochem 61: 809-860, 1992
46. Luo Q, Harmon E, Timms BG, Kretzner L: Novel expression patterns of the Myc/Max/Mad transcription factor network in developing murine prostate gland. J Urol 166: 1071-1077, 2001
47. Szeberenyi J: Gene activation pathways of nerve growth factor signaling: A minireview. Neurobiology 4: 1-11, 1996
48. Lee LA, Dang CV: c-Myc transrepression and cell transformation. Curr Topics Microbiol Immunol 224: 131-135, 1997
49. Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB: Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 60: 749-755, 2000
50. Xu B, Lin L, Rote NS: Identification of a stress-induced protein during human trophoblast differentiation by differential display analysis. Biol Reprod 61: 681-686, 1999
51. Kyle V, Bernstein M, Leclerc, J Met et al.: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53: 5269-5273, 1993
52. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR: Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7: 127-133, 1992
53. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA: Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc Natl Acad Sci USA 96: 8505-8510, 1999
54. Smale ST, Jain A, Kaufmann J, Emami KH, Lo K, Garraway IP: The initiator element: A paradigm for core promoter heterogeneity within metazoan protein-coding genes. Cold Spring Harbor Symp Quant Biol 63: 21-31, 1998
55. Nesbit CE, Tersak JM, Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016, 1999